Neural Therapeutics Inc.
NURL
CNSX
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 100.27% | -67.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.99% | -51.61% | |||
| Operating Income | -13.99% | 51.61% | |||
| Income Before Tax | -10.58% | 51.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.58% | 51.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.58% | 51.74% | |||
| EBIT | -13.99% | 51.61% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -9.09% | 52.17% | |||
| Normalized Basic EPS | -14.29% | 50.00% | |||
| EPS Diluted | -9.09% | 52.17% | |||
| Normalized Diluted EPS | -14.29% | 50.00% | |||
| Average Basic Shares Outstanding | 1.15% | -0.33% | |||
| Average Diluted Shares Outstanding | 1.15% | -0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||